GenoID Announces Breakthrough in Human Papillomavirus Testing
GenoID Ltd. is proud to announce the availability of aReal-Time Human Papillomavirus (HPV) test to detect all variants ofthe virus that may cause cervical cancer.
The new test is a breakthrough in the history of HPV diagnosticsbeing the first user-friendly, highly sensitive and specific testingkit using a real-time polymerase chain reaction (real-time PCR)method.
With GenoID's diagnostic kit, laboratories can provide testresults within three hours, and can significantly increase thereliability of HPV diagnostics by reducing the number of false resultsand test repetitions.
Other commercially available PCR tests for HPV require highlyskilled laboratory staff, while easy-to-use tests may not offer theprecision of PCR tests, and either take a minimum of eight hours forcompletion.
"Virtually any laboratory can provide reliable HPV testing withGenoID's new product," said Csaba Jeney, Head of Research at GenoID."We are proud to be the company which brought real-time technology toHPV testing.
"Actually, this easy-to-use and trustable kit contains over 50artificial DNA sequences making it probably the most complicated PCRreaction ever."
"We were convinced of the importance of an easy-to-use HPV testwhich does not compromise on quality and which can become accessibleto large patient populations. With our product, both a small clinicand a high-throughput, fully automated lab can provide HPV testing ina cost efficient manner," general manager Attila Erdos said.
About HPV and cervical cancer
Cervical cancer - caused by HPV - is the second most common cancerof women, but can be prevented with efficient HPV screening. It isestimated that more than 5 million new genital HPV cases occur eachyear.
About GenoID
GenoID Ltd. is developing and manufacturing diagnostic kits forsexually transmitted infections such as HPV, Chlamydia Trachomatis andHerpes Simplex. Last year GenoID introduced an HPV detection kit whichcan identify 50 types of HPV - more than any other test in the market.
In November 2005, the company jointly with the Semmelweis MedicalSciences University of Budapest received a grant to develop a newcervical cancer screening method to replace PAP smear.
GenoID, as a laboratory, provides diagnostic services for theHungarian healthcare system and for its clients in neighbouringcountries. Since its inception, GenoID has carried out over half amillion PCR tests using its own diagnostic kits.